Hepatocellular carcinoma or interferon-based therapy history attenuates sofosbuvir/ribavirin for Japanese genotype 2 hepatitis C virus

Table 1 Pretreatment characteristics of the patients (n = 182)

Pretreatment characteristics	Values
Age1, yr	60.1 ± 14.1
Age ≥ 70 yr	27.40%
Sex, M : F	122:60
Body height1, cm	163.0 ± 8.9
Body weight1, kg	62.3 ± 12.1
Liver cirrhosis	26.60%
History of HCC	15.90%
FIB-4 index2	2.63 (0.45-19.03)
FIB-4 index > 3.25	40.70%
Wisteria floribunda agglutinin+-Mac-2 binding protein2	1.94 (0.20-18.51)
Hyaluronic acid2, ng/mL	97.4 (10.0-2750.0)
History of IFN-based therapy	23.60%
IL28B-SNP rs8099917 TT/non TT	136/38/8
ITPA-SNP rs1127354 CC	129/45/8
HCV genotype 2A/2B/ND	109/70/3
HCV RNA2, logIU/mL	6.1 (1.2-7.6)
HCV RNA > 6 logIU/mL	58.80%
White blood cell count2, /mm3	4575 (1700-12010)
Hemoglobin2, g/dL	13.7 (10.1-17.6)
Platelet count2, /mm3	165 (38-389) × 103
Aspartate aminotransferase2, IU/L	41 (14-336)
Alanine aminotransferase2, IU/L	40 (5-391)
Albumin2, g/dL	4.0 (2.6-5.0)
Total bilirubin2, mg/dL	0.8 (0.3-3.0)
Blood urea nitrogen2, mg/dL	13 (5-28)
Creatinine2, mg/dL	0.71 (0.32-1.23)
Estimated glomerular filtration rate2, mL/min/1.73 m2	78.9 (42.6-164.2)

¹Mean ± SD;

²Median (range). M: Male; F: Female; HCC: Hepatocellular carcinoma; FIB: Fibrosis; IL28B: Interleukin-28B; SNP: Single nucleotide polymorphisms; ITPA: Inosine triphosphate pyrophosphatase; HCV: Hepatitis C virus.